Summary of the Conference Call for 诺禾致源 (Nuohe Zhiyuan) Company Overview - **Company**: 诺禾致源 (Nuohe Zhiyuan) - **Period**: January to September 2025 Key Financial Metrics - **Total Revenue**: 15.81 billion CNY, up 4.05% year-on-year [2][3] - **Q3 Revenue**: 5.41 billion CNY, up 3.47% year-on-year [3] - **Overseas Revenue**: 7.92 billion CNY, up 4.1% year-on-year, accounting for 50.09% of total revenue [2][3] - **Q3 Overseas Revenue**: 2.58 billion CNY, down 0.48% year-on-year [3] - **Domestic Revenue**: 7.89 billion CNY, up 4% year-on-year [2] - **Q3 Domestic Revenue**: 2.82 billion CNY, up 7.37% year-on-year, and up 8.61% quarter-on-quarter [5] - **Gross Margin**: 41.9%, down 0.7 percentage points year-on-year [10] - **Net Profit**: 1.16 billion CNY, down 10.17% year-on-year, with a net profit margin of 7.31% [11] - **R&D Investment**: 56.1 million CNY in Q3, focusing on emerging fields [12] Revenue Breakdown by Market - **Americas**: Q3 revenue down 12% due to changes in research funding and policy impacts [4] - **EMEA**: Q3 revenue down 12%, affected by project completion and funding transitions [4] - **Europe**: Q3 revenue up 19%, indicating strong performance [4] - **Customer Segmentation**: 70% of revenue from universities and research institutions, 30% from hospitals and enterprises [6] Product and Service Performance - **Life Sciences Research Services**: Revenue of 5.52 billion CNY, up 6.21% year-on-year [7] - **Monitoring and Sequencing Platform Services**: Revenue of 7.7 billion CNY, up 3.23% year-on-year, but Q3 revenue down 3.42% [7] - **Emerging Business Contributions**: Approximately 32% of total revenue, up 4 percentage points year-on-year, with a growth of about 20% [8] R&D and Innovation - **R&D Focus Areas**: Single-cell genomics, spatial genomics, proteomics, metabolomics, epigenetics, and long-read sequencing [12][18] - **AI Integration**: Progress in AI applications, particularly in omics data analysis and virtual cell modeling [20][28] Market Challenges and Strategies - **Domestic Market Competition**: Increased competition leading to a 30% price drop; company aims to reduce competition through mergers and acquisitions [16][23] - **Geopolitical Impact**: U.S. market affected by geopolitical tensions, but the company maintains strong relationships in key regions [21] - **Cash Flow Management**: Operating cash flow was negative 87 million CNY for the first nine months, but turned positive in Q3 at 77 million CNY [14] Future Outlook - **Expansion Plans**: Continued investment in overseas markets, including new laboratories in Singapore and Europe [30] - **Focus on NGS and AI**: Anticipated growth in NGS applications and AI integration to enhance research capabilities [24][28] Additional Insights - **Customer Base Growth**: Stable customer structure with a slight increase in contributions from universities and research institutions [6] - **Cash Flow Volatility**: Short-term fluctuations in cash flow due to proactive risk management strategies [14] - **Regulatory Environment**: Ongoing adjustments to align with changing policies in the domestic and international markets [26][27]

Core Viewpoint - The company announced a provision for asset impairment totaling approximately 24.53 million yuan to reflect its financial status and operational results as of September 30, 2025 [2] Financial Assessment - The company conducted a comprehensive evaluation of its financial assets, inventory, and long-term assets to determine potential impairment losses [2] - The impairment provision was made in accordance with the "Enterprise Accounting Standards" and the company's accounting policies and estimates [2] Meeting Announcement - The fourth meeting of the fourth board of directors is scheduled for October 23, 2025, to review the asset impairment provision proposal [2]

智通财经APP讯，诺禾致源(688315.SH)披露2025年第三季度报告，公司前三季度实现营收15.81亿元， 同比增长4.05%;归属于上市公司股东的净利润1.13亿元，同比下降16.05%;扣非净利润9002万元，同比下 降19.35%;基本每股收益0.28元。 ...

每经头条（nbdtoutiao）——四次登上央视，知名大佬"消失"5年，我们在水果仓库找到了他！从月薪 5000到千亿市值公司联席总裁，他45岁再创业 （记者 曾健辉） 截至发稿，诺禾致源市值为61亿元。 每经AI快讯，诺禾致源（SH 688315，收盘价：14.77元）10月23日晚间发布公告称，2025年前三季度， 公司计提信用减值损失和资产减值损失共计2453.21万元，导致公司2025年前三季度合并报表税前利润 总额减少2453.21万元，并相应减少报告期末所有者权益。 2024年1至12月份，诺禾致源的营业收入构成为：基因测序专业技术服务占比99.66%，其他业务占比 0.34%。 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-039 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 10 日（星期一）至 11 月 16 日（星期日）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@novogene.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 北京诺禾致源科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 24 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 17 日下午 13:00-14:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 北京诺禾致源科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-038 单位：万元 | 序号 | 项目 | 年前三季度计提金额 2025 | 备注 | | --- | --- | --- | --- | | 1 | 信用减值损失 | 2,435.86 | 应收账款、其他应收款的减值 | | 2 | 资产减值损失 | 17.34 | 存货的减值 | | | 合计 | 2,453.21 | | 注，以上明细与合计的差异系万元小数位数四舍五入影响。 北京诺禾致源科技股份有限公司 关于 2025 年前三季度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京诺禾致源科技股份有限公司（以下简称"公司"）于 2025 年 10 月 23 日 召开第四届董事会第四次会议，审议通过了《关于计提资产减值准备的议案》。现 将相关事项公告如下： 一、计提资产减值准备情况的概述 根据《企业会计准则》以及公司的会计政策、会计估计的相关规定，为客观、 公允地反映公司截至 2025 年 9 月 30 日的财务状况及 2025 年 ...

Core Viewpoint - The company reported a revenue of 1.581 billion yuan for the first three quarters, reflecting a year-on-year growth of 4.05%, while net profit attributable to shareholders decreased by 16.05% to 113 million yuan [1] Financial Performance - Revenue for the first three quarters reached 1.581 billion yuan, marking a 4.05% increase compared to the previous year [1] - Net profit attributable to shareholders was 113 million yuan, showing a decline of 16.05% year-on-year [1] - The net profit excluding non-recurring gains and losses was 90.0163 million yuan, down 19.35% year-on-year [1] - Basic earnings per share stood at 0.28 yuan [1]

北京诺禾致源科技股份有限公司 2025 年第三季度报告 证券代码：688315 证券简称：诺禾致源 北京诺禾致源科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是√否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 540,653,209.65 | 3.47 | 1,58 ...

诺禾致源公告称，公司于2025年10月23日召开会议，审议通过计提资产减值准备议案。基于谨慎性原 则，公司对截至2025年9月30日的相关资产进行评估，本期计提减值准备总额约2453.21万元，其中信用 减值损失2435.86万元、资产减值损失17.34万元。这将使公司2025年前三季度合并报表税前利润总额减 少2453.21万元，相应减少报告期末所有者权益。数据未经审计，以年度审计确认金额为准。董事会及 审计委员会均同意本次计提。 ...

Core Viewpoint - The stock price of Beijing Novogene Technology Co., Ltd. has shown fluctuations, with a year-to-date increase of 16.62% but a recent decline over various trading periods, indicating potential volatility in the market [1]. Company Overview - Beijing Novogene Technology Co., Ltd. was established on March 15, 2011, and went public on April 13, 2021. The company is located in Chaoyang District, Beijing, and specializes in providing gene testing and bioinformatics analysis services to research institutions, universities, medical institutions, and pharmaceutical companies [1]. - The company's revenue composition includes: sequencing platform services (50.03%), basic life science research services (34.05%), medical research and technical services (13.37%), and other services (2.54%) [1]. Financial Performance - As of June 30, 2025, Novogene reported a revenue of 1.04 billion yuan, representing a year-on-year growth of 4.36%. The net profit attributable to shareholders was 78.73 million yuan, with a slight increase of 1.03% year-on-year [2]. - The company has distributed a total of 82.47 million yuan in dividends since its A-share listing, with 58.46 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 2.18% to 9,802, while the average number of circulating shares per person decreased by 2.13% to 42,460 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 5.69 million shares, an increase of 2.71 million shares from the previous period. Hongde Advantage Leading Mixed Fund is the ninth largest shareholder, holding 1.61 million shares as a new entrant [3].